SCHEMBL6603466

SCHEMBL6603466

Nc1[c]cc(F)c(F)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28872401 0.77
SCHEMBL29015304 0.77
SCHEMBL5148314 0.77
SCHEMBL25181953 0.72 KDM1A (0.36)
SCHEMBL149390 0.71
SCHEMBL261271 0.67
SCHEMBL1101277 0.67
SCHEMBL1100275 0.67
SCHEMBL6561427 0.65
SCHEMBL972733 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104119285-B Compound and application thereof as estrogen-related receptor modulator 中国科学院广州生物医药与健康研究院 2016-06-29 CN claimed
CN-104119285-A Compound used as estrogen-related receptor regulator and application of compound GUANGZHOU INST BIOMED & HEALTH 2014-10-29 CN claimed
EP-3802549-B1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION HOFFMANN LA ROCHE (CH) 2023-03-01 EP disclosed
CN-110475777-B Novel pyrido [2,3-b ] indole compounds for the treatment and prevention of bacterial infections 豪夫迈·罗氏有限公司 2022-04-15 CN disclosed
US-20210238197-A1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2021-08-05 US disclosed
EP-3802549-A1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2021-04-14 EP disclosed
CN-112204037-A Novel oxoquinolizine compounds for the treatment and prevention of bacterial infections 豪夫迈·罗氏有限公司 2021-01-08 CN disclosed
WO-2019228940-A1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2019-12-05 WO disclosed
CN-110475777-A For treating and preventing new pyrido [2,3-b] benzazolyl compounds of bacterium infection HOFFMANN LA ROCHE 2019-11-19 CN disclosed
CN-107635994-A Imidazopyrimidine and imidazo-triazine derivative and include its pharmaceutical composition 爱思开生物制药株式会社 2018-01-26 CN disclosed
CN-107074810-A It is used as the tetrahydropyridine of 2 amino 5,5 difluoro 6 (methyl fluoride) 6 phenyl 3,4,5,6 of BACE1 inhibitor H.隆德贝克有限公司 2017-08-18 CN disclosed
CN-104119285-B Compound and application thereof as estrogen-related receptor modulator 中国科学院广州生物医药与健康研究院 2016-06-29 CN disclosed
CN-104119285-A Compound used as estrogen-related receptor regulator and application of compound GUANGZHOU INST BIOMED & HEALTH 2014-10-29 CN disclosed
CN-103221403-A Heterocyclic compounds and their use AMGEN INC 2013-07-24 CN disclosed
US-6800630-B2 CYTOSTATIC ACTIVITY, INHIBITORY ACTIVITY AGAINST A SIGNAL DERIVED FROM RAS ONCOGENE PRODUCTS SHIONOGI & CO., LTD. (JP) 2004-10-05 US disclosed
EP-1251129-B1 PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT SHIONOGI & CO (JP) 2004-06-09 EP disclosed
US-20030203894-A1 Pyrimidine derivatives having antitumor effect SHIONOGI & CO., LTD. (JP) 2003-10-30 US disclosed
EP-1251129-A1 PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT SHIONOGI & CO., LTD. (JP) 2002-10-23 EP disclosed
US-6420367-B1 RAS GENE SHIONOGO & CO., LTD. (JP) 2002-07-16 US disclosed
EP-1097933-A1 PYRIMIDINE DERIVATIVES EXHIBITING ANTITUMOR ACTIVITY SHIONOGI & CO., LTD. (JP) 2001-05-09 EP disclosed